These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9360504)

  • 1. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
    Mijatovic V; Kenemans P; Netelenbos JC; Peters-Muller ER; van Kamp GJ; Voetberg GA; van de Weijer PH; van der Mooren MJ
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3543-7. PubMed ID: 9360504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.
    Voetberg GA; Netelenbos JC; Kenemans P; Peters-Muller ER; van de Weijer PH
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1465-9. PubMed ID: 7962344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
    Pornel B; Chevallier O; Netelenbos JC
    Menopause; 2002; 9(3):171-8. PubMed ID: 11973440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
    van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
    Mijatovic V; Kenemans P; Netelenbos C; Jakobs C; Popp-Snijders C; Peters-Muller ER; van der Mooren MJ
    Fertil Steril; 1998 May; 69(5):876-82. PubMed ID: 9591496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study.
    Haines C; Chung T; Chang A; Masarei J; Tomlinson B; Wong E
    Arch Intern Med; 1996 Apr; 156(8):866-72. PubMed ID: 8774205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
    Schram JH; Boerrigter PJ; The TY
    Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Maturitas; 2004 Nov; 49(3):253-63. PubMed ID: 15488354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC; Rioux JE; Komer L; Gelfand M
    Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins.
    Haines CJ; Chung TK; Masarei JR; Tomlinson B; Lau JT
    Atherosclerosis; 1996 Jan; 119(2):215-22. PubMed ID: 8808498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
    Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
    Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.
    Gelfand M; Fugère P; Bissonnette F
    Maturitas; 1997 Mar; 26(2):125-32. PubMed ID: 9089562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.